Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2023 | 1224 | 2.350 |
Why?
|
| Insulin Resistance | 2 | 2022 | 415 | 0.600 |
Why?
|
| Biopsy, Needle | 3 | 2002 | 133 | 0.440 |
Why?
|
| Mammary Glands, Human | 4 | 2019 | 56 | 0.420 |
Why?
|
| Breast | 4 | 2007 | 191 | 0.420 |
Why?
|
| Physician Incentive Plans | 1 | 2013 | 9 | 0.400 |
Why?
|
| Weight Gain | 2 | 2022 | 166 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 45 | 0.380 |
Why?
|
| Medical Oncology | 1 | 2013 | 69 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 531 | 0.300 |
Why?
|
| Female | 23 | 2026 | 34095 | 0.280 |
Why?
|
| Mastectomy | 3 | 2022 | 56 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2023 | 91 | 0.250 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2026 | 2 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2005 | 44 | 0.220 |
Why?
|
| Genetic Testing | 1 | 2026 | 141 | 0.220 |
Why?
|
| Humans | 26 | 2026 | 65268 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 33 | 0.210 |
Why?
|
| Carcinoma, Lobular | 1 | 2004 | 26 | 0.210 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 36 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 50 | 0.210 |
Why?
|
| Middle Aged | 15 | 2026 | 18327 | 0.200 |
Why?
|
| Estrogens | 2 | 2023 | 115 | 0.200 |
Why?
|
| Intraoperative Period | 1 | 2003 | 34 | 0.190 |
Why?
|
| Postmenopause | 2 | 2023 | 238 | 0.190 |
Why?
|
| Biopsy | 2 | 2007 | 457 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2022 | 897 | 0.190 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 16 | 0.180 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 102 | 0.180 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 732 | 0.180 |
Why?
|
| Papilloma | 1 | 2002 | 12 | 0.180 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 48 | 0.180 |
Why?
|
| Insulin | 2 | 2022 | 695 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2023 | 336 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 373 | 0.150 |
Why?
|
| Mammography | 1 | 2022 | 291 | 0.150 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 524 | 0.150 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 130 | 0.150 |
Why?
|
| Epithelial Cells | 2 | 2022 | 413 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 156 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2022 | 3312 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 130 | 0.130 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 61 | 0.130 |
Why?
|
| Phenols | 1 | 2018 | 77 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 586 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 83 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 465 | 0.120 |
Why?
|
| Transcriptome | 1 | 2019 | 399 | 0.120 |
Why?
|
| Adult | 11 | 2026 | 17398 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 555 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2007 | 497 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 604 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 399 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 795 | 0.100 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 29 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 930 | 0.100 |
Why?
|
| Stereotaxic Techniques | 2 | 2007 | 30 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2019 | 924 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Exercise | 1 | 2020 | 966 | 0.090 |
Why?
|
| Parity | 1 | 2013 | 71 | 0.090 |
Why?
|
| Aged | 8 | 2026 | 15010 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1631 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6897 | 0.090 |
Why?
|
| Risk Factors | 4 | 2020 | 5447 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2013 | 282 | 0.090 |
Why?
|
| Norovirus | 1 | 2011 | 7 | 0.090 |
Why?
|
| Virus Shedding | 1 | 2011 | 17 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2011 | 45 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2013 | 400 | 0.080 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 67 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 47 | 0.080 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 81 | 0.080 |
Why?
|
| Diarrhea | 1 | 2011 | 73 | 0.080 |
Why?
|
| Stem Cells | 1 | 2013 | 276 | 0.080 |
Why?
|
| Disease Progression | 3 | 2023 | 1221 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2003 | 488 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 464 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 426 | 0.070 |
Why?
|
| Therapeutic Touch | 1 | 2007 | 2 | 0.070 |
Why?
|
| Grounded Theory | 1 | 2026 | 18 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1562 | 0.060 |
Why?
|
| Uncertainty | 1 | 2026 | 40 | 0.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2005 | 17 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 32 | 0.060 |
Why?
|
| Pain Management | 1 | 2007 | 174 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 400 | 0.050 |
Why?
|
| United States | 2 | 2013 | 8122 | 0.050 |
Why?
|
| Cyclohexanols | 1 | 2004 | 17 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 319 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 11 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1284 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 38 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2004 | 87 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 5624 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 544 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 364 | 0.050 |
Why?
|
| Decision Making | 1 | 2026 | 417 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 259 | 0.050 |
Why?
|
| Vacuum | 1 | 2002 | 8 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2002 | 30 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 643 | 0.040 |
Why?
|
| Equipment Design | 1 | 2003 | 363 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5801 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2026 | 752 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 97 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 439 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 41 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 121 | 0.040 |
Why?
|
| Histological Techniques | 1 | 1999 | 19 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2020 | 102 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1999 | 77 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 46 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 90 | 0.040 |
Why?
|
| Apoptosis | 2 | 2020 | 1098 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2768 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 853 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1274 | 0.040 |
Why?
|
| Calcinosis | 1 | 1999 | 84 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4822 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1704 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 223 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 160 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 139 | 0.030 |
Why?
|
| Credentialing | 1 | 1997 | 15 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 16 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 63 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 328 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1164 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1113 | 0.030 |
Why?
|
| Data Collection | 1 | 1997 | 382 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1997 | 123 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 299 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1039 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1785 | 0.030 |
Why?
|
| General Surgery | 1 | 1997 | 210 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2007 | 343 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2152 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2158 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1482 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 1233 | 0.020 |
Why?
|
| Stomatitis | 1 | 2013 | 8 | 0.020 |
Why?
|
| Radiology | 1 | 1997 | 263 | 0.020 |
Why?
|
| Niacinamide | 1 | 2013 | 33 | 0.020 |
Why?
|
| Capecitabine | 1 | 2013 | 14 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 32 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 45 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2013 | 68 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 60 | 0.020 |
Why?
|
| Male | 3 | 2026 | 31123 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 243 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 296 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 113 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1997 | 706 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2013 | 80 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 416 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2301 | 0.020 |
Why?
|
| Gynecomastia | 1 | 2011 | 11 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 742 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 857 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 122 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 105 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 252 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3769 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 381 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6318 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3154 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1120 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 142 | 0.020 |
Why?
|
| Human papillomavirus 6 | 1 | 2005 | 4 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 15 | 0.010 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 35 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 142 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 2375 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 11131 | 0.010 |
Why?
|
| Oncogenes | 1 | 2005 | 70 | 0.010 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2004 | 15 | 0.010 |
Why?
|
| Anxiety | 1 | 2007 | 427 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 700 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 180 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 896 | 0.010 |
Why?
|
| Analgesics | 1 | 2004 | 102 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 21373 | 0.010 |
Why?
|